Literature DB >> 17206947

Oesophageal mucosal involvement in patients with systemic sclerosis receiving proton pump inhibitor therapy.

I Marie1, P Ducrotte, P Denis, M F Hellot, H Levesque.   

Abstract

AIM: To assess the prevalence of oesophagitis, Barrett's oesophagus (BE) and other oesophageal mucosal abnormalities in patients with systemic sclerosis (SSc) without prior selection on digestive clinical presentation. We also investigated the association between oesophageal endoscopic and manometric data with clinical manifestations of SSc.
METHODS: Oesophageal endoscopy and manometry were performed in 133 consecutive patients with SSc, receiving proton pump inhibitor (PPI) therapy since SSc diagnosis.
RESULTS: Endoscopy revealed oesophagitis in 43 patients (32.3%), BE in 9 patients (6.8%), candidiasis in 7 patients (5.3%) and hyperplastic polyp arising in ectopic gastric mucosa in 1 patient. Patients with severe oesophageal motor impairment further exhibited a higher prevalence of interstitial lung disease (ILD) when compared with those without.
CONCLUSION: Our study underlines the high frequency of oesophageal mucosal abnormalities in unselected SSc patients receiving long-term PPI therapy. A relationship between oesophagitis/BE and severe manometric motor disturbances was established; these patients may require a higher regimen of PPI. Finally, our series indicates a correlation between severe oesophageal motor disturbances and evidence for ILD in patients, suggesting that gastro-oesophageal reflux may be one of the contributing factors of ILD in SSc; this subgroup of patients may require close monitoring of lung parameters.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17206947     DOI: 10.1111/j.1365-2036.2006.03180.x

Source DB:  PubMed          Journal:  Aliment Pharmacol Ther        ISSN: 0269-2813            Impact factor:   8.171


  18 in total

1.  Relationship between esophageal motility abnormalities and skin or lung involvements in patients with systemic sclerosis.

Authors:  Shiko Kuribayashi; Sei-Ichiro Motegi; Kenichiro Hara; Yasuyuki Shimoyama; Hiroko Hosaka; Akiko Sekiguchi; Kouichi Yamaguchi; Osamu Kawamura; Takeshi Hisada; Osamu Ishikawa; Motoyasu Kusano; Toshio Uraoka
Journal:  J Gastroenterol       Date:  2019-04-01       Impact factor: 7.527

Review 2.  Management of Esophageal Squamous Cell Carcinoma with Definitive Chemoradiotherapy in a Patient with Scleroderma: Case Report and Review of the Literature.

Authors:  David P Horowitz; Balazs Halmos; John Poneros; Joshua Sonett; Helen Remotti; Ryan J Burri
Journal:  J Gastrointest Cancer       Date:  2012-09

Review 3.  Pharmacotherapy of systemic sclerosis.

Authors:  Arnold E Postlethwaite; L Jeff Harris; Syed H Raza; Swapna Kodura; Titilola Akhigbe
Journal:  Expert Opin Pharmacother       Date:  2010-04       Impact factor: 3.889

Review 4.  Environmental - lifestyle related factors.

Authors:  Sabine Roman; John E Pandolfino
Journal:  Best Pract Res Clin Gastroenterol       Date:  2010-12       Impact factor: 3.043

Review 5.  Gastrointestinal manifestations of scleroderma: recent progress in evaluation, pathogenesis, and management.

Authors:  Genevieve Gyger; Murray Baron
Journal:  Curr Rheumatol Rep       Date:  2012-02       Impact factor: 4.592

Review 6.  Advances in the evaluation and management of esophageal disease of systemic sclerosis.

Authors:  Dustin A Carlson; Monique Hinchcliff; John E Pandolfino
Journal:  Curr Rheumatol Rep       Date:  2015-01       Impact factor: 4.592

7.  Early endoscopy in systemic sclerosis without gastrointestinal symptoms.

Authors:  Rene Thonhofer; Cornelia Siegel; Markus Trummer; Winfried Graninger
Journal:  Rheumatol Int       Date:  2010-08-14       Impact factor: 2.631

8.  Clinical Assessment of Gastrointestinal Involvement in Patients with Systemic Sclerosis.

Authors:  Timothy Kaniecki; Tsion Abdi; Zsuzsanna H McMahan
Journal:  Med Res Arch       Date:  2020-10-29

Review 9.  The primary care physician in the early diagnosis of systemic sclerosis: the cornerstone of recognition and hope.

Authors:  Lesley Ann Saketkoo; Jeanette H Magnus; Mittie K Doyle
Journal:  Am J Med Sci       Date:  2014-01       Impact factor: 2.378

Review 10.  Points to consider for clinical trials of the gastrointestinal tract in systemic sclerosis.

Authors:  Daniel E Furst; Yolanda Braun-Moscovic; Dinesh Khanna
Journal:  Rheumatology (Oxford)       Date:  2017-09-01       Impact factor: 7.580

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.